Literature DB >> 12493148

Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis.

Stacey L Berg1, Marc C Chamberlain.   

Abstract

Metastasis to the leptomeninges occurs in many common cancers, including leukemia; lung, breast, and gastrointestinal cancers; and tumors of the brain. By way of the flow of cerebrospinal fluid, leptomeningeal metastasis spreads throughout the neuraxis. Consequently, therapy for leptomeningeal metastasis must be directed to the entire central nervous system (CNS). Treatment often consists of involved-field radiotherapy, systemic chemotherapy, and intrathecal chemotherapy. However, because meningeal spread occurs most often in advanced disease, treatment is mainly palliative, except in childhood leukemia, where durable remission has been reported. This article outlines the role of systemic and intrathecal chemotherapy in patients with leptomeningeal metastases. Strategies for symptom management in these patients are also described.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12493148     DOI: 10.1007/s11912-003-0084-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  112 in total

1.  Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium.

Authors:  W A Bleyer
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

Review 2.  Neoplastic meningitis.

Authors:  S A Grossman; T J Moynihan
Journal:  Neurol Clin       Date:  1991-11       Impact factor: 3.806

3.  Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis.

Authors:  M C Chamberlain; P Kormanik; M Glantz
Journal:  Oncol Rep       Date:  1998 Mar-Apr       Impact factor: 3.906

Review 4.  Paraplegia following intrathecal chemotherapy.

Authors:  J H Saiki; S Thompson; F Smith; R Atkinson
Journal:  Cancer       Date:  1972-02       Impact factor: 6.860

5.  Remission induction of meningeal leukemia with high-dose intravenous methotrexate.

Authors:  F M Balis; J L Savitch; W A Bleyer; G H Reaman; D G Poplack
Journal:  J Clin Oncol       Date:  1985-04       Impact factor: 44.544

6.  Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.

Authors:  R C Donehower; J E Karp; P J Burke
Journal:  Cancer Treat Rep       Date:  1986-09

7.  The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A).

Authors:  A E Evans; E S Gilbert; R Zandstra
Journal:  Cancer       Date:  1970-08       Impact factor: 6.860

Review 8.  Central nervous system pharmacology of antileukemic drugs.

Authors:  F M Balis; D G Poplack
Journal:  Am J Pediatr Hematol Oncol       Date:  1989

9.  Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.

Authors:  M J Glantz; W A Hall; B F Cole; B S Chozick; C M Shannon; L Wahlberg; W Akerley; L Marin; H Choy
Journal:  Cancer       Date:  1995-06-15       Impact factor: 6.860

10.  Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985.

Authors:  R D Gelber; S E Sallan; H J Cohen; M Donnelly; V Dalton; F Tobia; L A Clavell; N J Tarbell
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

View more
  6 in total

1.  Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.

Authors:  Jodi A Muscal; Yongkai Sun; Jed G Nuchtern; Robert C Dauser; Leticia H McGuffey; Brian W Gibson; Stacey L Berg
Journal:  Cancer Chemother Pharmacol       Date:  2011-11-23       Impact factor: 3.333

Review 2.  Novel approaches to treating leptomeningeal metastases.

Authors:  Jai Grewal; Marlon Garzo Saria; Santosh Kesari
Journal:  J Neurooncol       Date:  2011-08-28       Impact factor: 4.130

3.  Role of ventriculoperitoneal shunting in patients with neoplasms of the central nervous system: An analysis of 59 cases.

Authors:  Fares Nigim; Jonathan F Critchlow; Ekkehard M Kasper
Journal:  Mol Clin Oncol       Date:  2015-08-31

Review 4.  Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making.

Authors:  Nayan Lamba; Tim Fick; Rhishi Nandoe Tewarie; Marike L Broekman
Journal:  J Neurooncol       Date:  2018-07-18       Impact factor: 4.130

Review 5.  Treatment Options in Refractory Autoimmune Encephalitis.

Authors:  Alessandro Dinoto; Sergio Ferrari; Sara Mariotto
Journal:  CNS Drugs       Date:  2022-08-02       Impact factor: 6.497

6.  Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis.

Authors:  Ya-Lan Wu; Lin Zhou; You Lu
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.